ReviewPLoS medicine2012
HIV treatment as prevention: issues in economic evaluation.
Review in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- A Game Theoretic Analysis of Competition Between Vaccine and Drug Companies during Disease Contraction and Recovery.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation.Health economics review · 2021Article
- Economic evaluation of HIV testing options for low-prevalence high-income countries: a systematic review.Health economics review · 2021Article
- Getting to 90-90-90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini.Current HIV/AIDS reports · 2020Review
- Evaluation of A Phylogenetic Pipeline to Examine Transmission Networks in A Canadian HIV Cohort.Microorganisms · 2020Article
- Specific ActivationJournal of virology · 2019Article
- HIV Treatment Substantially Decreases Hospitalization Rates: Evidence From Rural South Africa.Health affairs (Project Hope) · 2018Article
- Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS.Health economics review · 2017Article
- Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.PLoS computational biology · 2015Article
- Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.BMC public health · 2015Article
- Scaled-Up Mobile Phone Intervention for HIV Care and Treatment: Protocol for a Facility Randomized Controlled Trial.JMIR research protocols · 2015Article
- Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest?Journal of acquired immune deficiency syndromes (1999) · 2014Review
- A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research.BMC medical ethics · 2014Article
- Prevalence of Anogenital Warts in Men with HIV/AIDS and Associated Factors.The open AIDS journal · 2014Article
- Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria.AIDS (London, England) · 2013Review
- Economics of antiretroviral treatment vs. circumcision for HIV prevention.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Human resources needs for universal access to antiretroviral therapy in South Africa: a time and motion study.Human resources for health · 2012Article
- HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.PLoS medicine · 2012Review
- HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.PLoS medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Meyer-Rath and Over assert in another article in the July 2012 PLoS Medicine Collection, "Investigating the Impact of Treatment on New HIV Infections", that economic evaluations of antiretroviral therapy (ART) in currently existing programs and in HIV treatment as prevention (TasP) programs should use cost functions that capture cost dependence on a number of factors, such as scale and scope of delivery, health states, ART regimens, health workers' experience, patients' time on treatment, and the distribution of delivery across public and private sectors. We argue that for particular evaluation purposes (e.g., to establish the social value of TasP) and from particular perspectives (e.g., national health policy makers) less detailed cost functions may be sufficient. We then extend the discussion of economic evaluation of TasP, describing why ART outcomes and costs assessed in currently existing programs are unlikely to be generalizable to TasP programs for several fundamental reasons. First, to achieve frequent, widespread HIV testing and high uptake of ART immediately following an HIV diagnosis, TasP programs will require components that are not present in current ART programs and whose costs are not included in current estimates. Second, the early initiation of ART under TasP will change not only patients' disease courses and treatment experiences--which can affect behaviors that determine clinical treatment success, such as ART adherence and retention--but also quality of life and economic outcomes for HIV-infected individuals. Third, the preventive effects of TasP are likely to alter the composition of the HIV-infected population over time, changing its biological and behavioral characteristics and leading to different costs and outcomes for ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.